^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HR negative

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Entrez ID:
1d
The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets. (PubMed, Curr Cancer Drug Targets)
The expression of the PD-L1 and MET genes is remarkably associated with worse tumor clinicopathologic features and poor prognosis in patients with breast cancer. Further investigations using combination drug regimens targeting PD-L1 and MET are important, particularly in breast tumors expressing high levels of both proteins.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • HER-2 positive • PD-L1 overexpression • MET overexpression • HR negative • MET expression • HER-2 negative + HR negative + PD-L1 expression • HER-2 positive + HR negative • HR negative + HER-2 positive
4d
Single-cell multiplex immunocytochemistry in cell block preparations of metastatic breast cancer confirms sensitivity of GATA-binding protein 3 over gross cystic disease fluid protein 15 and mammaglobin. (PubMed, Cancer Cytopathol)
For a single marker, GATA3 displayed the highest sensitivity. The addition of MMG for hormone receptor-positive breast cancers and GCDFP15 for hormone receptor-negative breast cancers further increased sensitivity. The low proportion of multimarker-positive cells suggested that the coexpression observed with traditional ICC is attributable to intratumoral heterogeneity, not genuine coexpression.
Journal • Cell block • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • GATA3 (GATA binding protein 3)
|
ER positive • HR positive • HER-2 overexpression • HR negative • PGR positive • EGFR positive • HER-2 overexpression + HR negative • HER-2 overexpression + HR positive
5d
Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors-impact on breast adipose oxylipin and DNA methylation patterns. (PubMed, medRxiv)
These data provide evidence of both metabolic and epigenetic effects of n-3 PUFAs in breast adipose tissue, elucidating novel mechanisms of action for high-dose EPA+DHA-mediated prevention of ERPR(-) breast cancer. Clinicaltrials.gov identifier NCT02295059.
Journal • Epigenetic controller
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR negative • PGR negative
20d
Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study. (PubMed, Cancer)
For patients with T1cN0M0-stage HER2+ breast cancer, NAT demonstrated comparable OS and BCSS to AT. Patients who achieved pCR after NAT exhibited significantly better survival outcomes compared with those who received AT.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative • EGFR positive
21d
Exploring angiogenic pathways in breast cancer: Clinicopathologic correlations and prognostic implications based on gene expression profiles from a large-scale genomic dataset. (PubMed, PLoS One)
In this dataset of patients with breast cancer, the expression levels of 8 different pro-angiogenic genes revealed remarkable differences in terms of their association with clinicopathologic tumor characteristics and prognosis. The expression of ANGPTs and PDGFs was associated with adverse tumor features, worse prognosis, and reduced survival in patients. Targeting ANGPTs and PDGF pathways could provide new insights for effective anti-angiogenic drugs in breast cancer.
Journal • Gene Expression Profile
|
HER-2 (Human epidermal growth factor receptor 2) • HGF (Hepatocyte growth factor) • ANGPT2 (Angiopoietin 2) • FGF2 (Fibroblast Growth Factor 2) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B)
|
HER-2 positive • HR negative • VEGFA expression • FGF1 expression • HER-2 positive + HR negative
21d
Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer. (PubMed, Am J Case Rep)
The TCbHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) as neoadjuvant chemotherapy was given. Our clinical experience suggests that neoadjuvant chemotherapy followed by modified radical mastectomy can be effective for treating such rare cases. The patient achieved pCR, which can provide a therapeutic strategy for effective treatment of similar OBCs.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR negative • HER-2 positive + HR negative
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
22d
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis. (PubMed, J Clin Oncol)
These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.
Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative
27d
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. (PubMed, Nat Med)
I-SPY2.2 uses a sequential multiple assignment randomization trial design that includes three sequential blocks of biologically targeted neoadjuvant treatment: the experimental agent(s) (block A), a taxane-based regimen tailored to the tumor subtype (block B) and doxorubicin-cyclophosphamide (block C). Dato-DXd was particularly active in the hormone receptor-negative/HER2-Immune-DNA repair deficiency- signature, warranting further investigation, and was safe in other subtypes in patients who followed the treatment strategy. ClinicalTrials.gov registration: NCT01042379 .
P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • DRD (DNA Repair Deficiency)
|
HER-2 negative • DDR • HR negative • DRD • HER-2 negative + HR negative
|
doxorubicin hydrochloride • cyclophosphamide • datopotamab deruxtecan (DS-1062a)
29d
Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy. (PubMed, Am J Cancer Res)
HER-2 zero to low conversion was associated with better DFS in patients who are HER-2 zero. These results provide a valuable reference for the potential application of anti-HER-2 ADC in an adjuvant setting for patients with residual disease after NAC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative • HER-2 amplification + HR-positive • HER-2 negative + HR negative
29d
Radiotherapy is recommended for hormone receptor-negative older breast cancer patients after breast conserving surgery. (PubMed, Sci Rep)
Moreover, RT improved OS and CSS in hormone receptor-negative older breast cancer patients who underwent BCS. In addition, the proposed nomograms more accurately predicted OS and CSS for hormone receptor-negative older breast cancer patients after BCS.
Journal • Surgery
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative
1m
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. (PubMed, J Clin Oncol)
The iDFS benefit was seen in the hormone receptor-negative (HR, 0.82 [95% CI, 0.64 to 1.06]) and HR+ cohorts (HR of 0.75 [95% CI, 0.61 to 0.92]). Despite improvement in overall iDFS, the addition of pertuzumab did not improve OS at this third interim analysis.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative • EGFR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
1m
Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. (PubMed, Ann Surg Oncol)
Over 90% of patients with clinically node-negative, microinvasive and T1a breast cancer remain pathologically node-negative following axillary staging. However, higher rates of nodal disease were found among Black patients, older patients, and patients with lobular cancer and significant comorbidities.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR negative • EGFR positive • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative
1m
Complete response and long-term survival to endocrine monotherapy in a patient with metastatic breast cancer in a low-income country: a case report. (PubMed, J Med Case Rep)
This case demonstrates a long-lasting complete response to metastatic breast cancer with malignant pleural effusion. This shows the validity of endocrine therapy in recurrent hormone receptor-positive breast cancer, especially in countries that cannot afford targeted therapies or genetic tests. It also highlights the necessity for a better understanding of the prognostic and predictive factors.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative • EGFR positive
5ms
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer. (PubMed, Cancer Treat Rev)
Finally, the distinct biology of triple-positive tumors may yield the rationale for considering combinations within antibody-drug conjugate regimens. Accordingly, in this review, we summarized the current evidence and rationale for considering TPBC as a different entity, in which distinct therapeutical approaches leveraging on the different biological profile of TPBC may result in superior anticancer regimens and improved patient-centric outcomes.
Journal • Review • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 expression • HR negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
5ms
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative
|
capecitabine
5ms
Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic Trial. (PubMed, JCO Glob Oncol)
In LABC, we demonstrated the survival benefit of BCS and the prognostic effect of the response to available neoadjuvant treatments despite an important variability in access to key treatments. The MPBCS represents a significant step forward in understanding the real-world implementation of oncologic procedures in LA.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HR negative • EGFR positive
|
Herceptin (trastuzumab)
6ms
PERGIQUAL: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HR negative
6ms
Survival outcomes for women with a solitary extracranial metastasis from breast cancer. (PubMed, Breast)
Among patients with a solitary extracranial metastasis from breast cancer, TNBC was associated with the poorest OS and DPFS rates. Identification of other significant prognostic factors for oligometastatic breast cancer patients may inform guidelines for metastasis directed treatments.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • HR positive + HER-2 positive • PTEN mutation + HR positive • HR negative + HER-2 positive
6ms
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures. (PubMed, Clin Transl Oncol)
Our findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative
6ms
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. (PubMed, Lancet Oncol)
In our study, a third of patients with stage II-III hormone receptor-negative and HER2-positive breast cancer had a complete pathological response after only three cycles of neoadjuvant systemic therapy. A complete response on breast MRI could help identify early complete responders in patients who had hormone receptor negative tumours. An imaging-based strategy might limit the duration of chemotherapy in these patients, reduce side-effects, and maintain quality of life if confirmed by the analysis of the 3-year event-free survival primary endpoint. Better monitoring tools are needed for patients with hormone receptor-positive and HER2-positive breast cancer.
P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HR negative • HR positive + HER-2 positive • HR negative + HER-2 positive
|
Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab)
6ms
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. (PubMed, Eur J Nucl Med Mol Imaging)
P2; These results highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate the selection of HER2+ EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy.
Journal • FDG PET
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HR negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
7ms
TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer. (PubMed, Cancers (Basel))
Regarding recurrence-free survival, the prognosis was poor in the TP53 and/or BRCA1 mutation-positive groups, especially in triple-negative breast cancer (TNBC) patients. In conclusion, the results of this study indicate that ctDNA with liquid biopsy could identify the poor prognosis group before treatment among TNBC patients and for those for whom optimal treatment selection is desirable; additionally, optimal treatment could be selected according to the ctDNA analysis results.
Journal • BRCA Biomarker • Circulating tumor DNA
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
TP53 mutation • BRCA1 mutation • HR negative
7ms
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study. (PubMed, Clin Transl Oncol)
Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.
Journal • Real-world evidence • Real-world
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
7ms
Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer. (PubMed, JAMA Netw Open)
Additionally, patients with ERBB2-low and low TILs tumors had better BCSM (subdistribution HR, 0.36; 95% CI, 0.14-0.92; P = .03). These findings suggest that there were clinical, pathological, and epidemiological differences between ERBB2-low and ERBB2-negative BC, raising the possibility that ERBB2-low might be a unique biologic entity.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR negative
7ms
BIRC5 expression by race, age and clinical factors in breast cancer patients. (PubMed, Breast Cancer Res)
Black and younger women with breast cancer have a higher burden of BIRC5-high tumors than older and non-Black women. Emerging anti-survivin treatment strategies may be an important future direction for equitable breast cancer outcomes.
Journal
|
ER (Estrogen receptor) • BIRC5 (Baculoviral IAP repeat containing 5)
|
ER positive • HR negative • ER negative • BIRC5 expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
7ms
Txnrd1 as a prognosticator for recurrence, metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients. (PubMed, Heliyon)
Txnrd1High MDA-MB-231 cells exhibit significant ROS generation and reduced viability after doxorubicin treatment compared to Txnrd1Low MCF7 cells. Corroborating with findings from meta-analysis, Txnrd1 depletion leads to decreased survival, enhanced sensitivity to radiation induced killing, poor scratch-wound healing, and reduced invasion potential in MDA-MB-231 cells. Thus, Txnrd1 appears to be a potential predictor of recurrence, metastasis and therapy response in breast cancer patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative • HR negative + HER-2 positive
|
doxorubicin hydrochloride
7ms
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer (clinicaltrials.gov)
P2, N=1008, Recruiting, Fudan University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification • HR negative • PGR expression
|
tamoxifen • capecitabine • Irene (pyrotinib) • exemestane
7ms
Stromal Type I Collagen in Breast Cancer: Correlation to Prognostic Biomarkers and Prediction of Chemotherapy Response. (PubMed, Clin Breast Cancer)
Low stromal type I collagen mRNA and protein expression are associated with unfavourable tumour characteristics in breast cancer. Stromal type I collagen might predict chemotherapy response.
Journal • Stroma
|
COL1A1 (Collagen Type I Alpha 1 Chain)
|
HR negative
7ms
Clinical characteristics and prognostic factors of breast cancer patients with tumor deposits in the ipsilateral axillary region (PubMed, Zhonghua Zhong Liu Za Zhi)
Therefore, a clinicopathological staging system taking into account tumor deposits should be developed. Since the number of tumor deposits affects the risk of recurrence and metastasis of breast cancer patients, we recommend that the number of tumor deposits should be reported in detail in the pathological report after breast cancer surgery.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 expression • HR negative • EGFR positive • PGR expression
8ms
Prognostic implications of HER2NEU-low in metastatic breast cancer. (PubMed, Cancer Med)
In the largest such analysis performed to date, our study demonstrates a small but statistically significant association with improved survival for HER2-low tumors compared to HER2-negative tumors in MBC.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative
8ms
Increased PIEZO1 Expression Is Associated with Worse Clinical Outcomes in Hormone-Receptor-Negative Breast Cancer Patients. (PubMed, Cancers (Basel))
Our results also demonstrated a decrease in CD8+ and CD4+ T cell infiltration in high-PIEZO1 HR-negative tumors. Further investigations are necessary to elucidate the mechanistic roles of PIEZO1 in HR-negative breast cancer.
Clinical data • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
HR positive • HR negative
8ms
High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer. (PubMed, Cancers (Basel))
In HER2-negative BC, the CD163+ TAM count was not significantly associated with survival. These results suggest that a high CD163+ TAM count predicts an inferior outcome, especially in HER2+ BC patients, and as adjuvant trastuzumab did not overcome the poor prognostic effect, combination treatments including therapies targeting the macrophage function could represent an effective therapeutic approach in HER2+ BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
HR positive • HER-2 negative • HR negative
|
Herceptin (trastuzumab)
8ms
ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features. (PubMed, J Pathol Clin Res)
ERBB2-amplified ILBC is a distinct molecular subgroup with frequent coamplification of CDK12, whereas ERBB2 sequence mutations occur only in ERBB2-unamplified ILBC. CDK12/ERBB2 co-amplification may explain the poor prognosis and therapy resistance of ERBB2-amplified ILBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CDK12 (Cyclin dependent kinase 12) • CDH1 (Cadherin 1) • SOX10 (SRY-Box 10)
|
HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 negative • HR negative • CDK12 mutation • CDH1 mutation • CDK12 amplification
8ms
Age-related phenotypes in breast cancer: A population-based study. (PubMed, Int J Cancer)
We point to aggressive phenotypes and increased tumor cell proliferation in breast cancer of the young. Hence, tumors of young breast cancer patients may present unique biological features, also when accounting for screen/interval differences, that may open for new clinical opportunities, stratifying treatment by age.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative
8ms
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. (PubMed, Eur J Cancer)
immune spatial classification on immune cells infiltrates seems crucial and could help patients' selection in clinical trial and greatly improve responses to specific therapies.
Journal • Immune cell
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
HR negative
|
cyclophosphamide • methotrexate
8ms
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 negative • HR negative
|
VENTANA PD-L1 (SP142) Assay
|
Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
9ms
NRG-BR005: Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery (clinicaltrials.gov)
P2, N=175, Suspended, NRG Oncology | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
Trial completion date • Trial primary completion date • Surgery • Biopsy
|
PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR negative
9ms
Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI. (PubMed, Br J Radiol)
A nomogram incorporating MRI and US with clinicopathologic variables was developed to provide a brief and concise approach in predicting pCR to assist clinicians in making treatment decisions early.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative • EGFR positive
9ms
Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments. (PubMed, BMC Cancer)
Guidance on tailored precision therapy with consideration of genomic mutations was possible for some patients with information provided by F1CDx. Clinicians should consider using F1CDx at turning points in the course of the disease.
Journal • Tumor mutational burden • PARP Biomarker • BRCA Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • CDH1 (Cadherin 1)
|
BRCA2 mutation • HR positive • PIK3CA mutation • PTEN mutation • HR negative
|
FoundationOne® CDx • FoundationOne® Liquid CDx
9ms
Predictive factors for complete pathological response in hormone receptor-negative breast cancer patients undergoing neoadjuvant chemotherapy. (PubMed, Pathol Res Pract)
In conclusion, hormone receptor-negative breast tumors stand to benefit from increased pCR rates if they encompass a DCIS component and exhibit CD10 expression while lacking EGFR expression. These findings underscore the importance of comprehensive profiling in predicting pCR outcomes in hormone receptor-negative breast cancer patients undergoing neoadjuvant chemotherapy.
Journal
|
EGFR (Epidermal growth factor receptor) • MME (Membrane Metalloendopeptidase)
|
EGFR expression • HR negative
9ms
Loss-Of-Heterozygosity As A Biomarker For Genomic Instability And Poor Outcomes In Endometrial Cancer (ESGO 2024)
Higher LOH was correlated with hormone-receptor-negative tumors and poorer survival rates. LOH may serve as a valuable tool for identifying EC cases with high genomic instability that could potentially benefit from PARP inhibitors.
PARP Biomarker • MSi-H Biomarker • BRCA Biomarker
|
ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • POLE (DNA Polymerase Epsilon) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
TP53 mutation • BRCA1 mutation • MSI-H/dMMR • PIK3CA mutation • PTEN mutation • ARID1A mutation • POLE mutation • HR negative • PGR negative
|
FoundationOne® CDx
9ms
Enrollment open • Metastases
|
HER-2 positive • HR positive • HR negative
|
Enhertu (fam-trastuzumab deruxtecan-nxki)